Multiple outlets report that the U.S. Food and Drug Administration (FDA) has issued a voluntary recall affecting nearly 370,000 bottles of the antidepressant duloxetine. The concern is that certain batches may contain higher-than-expected levels of a cancer-causing chemical or carcinogenic compound. Coverage indicates the recall is classified as a Class II action, which generally involves situations where exposure could cause health consequences, but the likelihood of serious harm is lower than in Class I cases.
The reports specify that the recall applies to selected lots of duloxetine capsules in 30 mg and 60 mg strengths. The distributor initiates the recall after suspected contamination is detected or identified during quality review. While the contaminant is described as carcinogenic, sources also emphasize that cancer risk is generally associated with long-term, high-level exposure rather than short-term use.
Patients are advised not to stop medication abruptly without medical guidance and to consult their healthcare provider about next steps, including whether an alternative supply is needed. Details of affected lots are tied to the FDA recall notice.
